Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.58 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13466161 | 0.82 | MEN1 (0.55) | LPLLIPGLMNAPKMNOTUM | |
| SCHEMBL1502728 | 0.81 | LMNA (0.40) | LPLLIPGLMNAPKMNOTUM | |
| SCHEMBL13611193 | 0.80 | PKM (0.46) | LPLLIPGLMNAPKMNOTUM | |
| SCHEMBL13466831 | 0.78 | LPL (0.42) | LPLLIPGLMNAPKMNOTUM | |
| SCHEMBL24608995 | 0.76 | LIPG (0.83) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL2707320 | 0.76 | LIPG (0.83) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL10768177 | 0.76 | PKM (0.78) | LMNAPKMNOTUMKEAP1GAA | |
| SCHEMBL11996134 | 0.75 | LIPG (0.62) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL228212 | 0.74 | LPL (0.71) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1372253 | 0.74 | LIPG (0.67) | LPLLIPGLMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9266834-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266834-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2016-02-23 | — | — | US | disclosed |
| EP-2426125-B1 | 1,4 disubstituted 3 cyano pyridone derivatives and their use as positive allosteric modulators of mGluR2 receptors | JANSSEN PHARMACEUTICALS INC (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20140315903-A1 | 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors | JANSSEN PHARMACEUTICALS INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315903-A1 | 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors | JANSSEN PHARMACEUTICALS INC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8841323-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841323-B2 | 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-09-23 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008141020-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2007104783-A2 | 1,4 -DI SUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPT0R MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| EP-1670757-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315903-A1 | 1, 4-Disubstituted 3-Cyano-Pyridone Derivatives and Their Use As Positive Allosteric Modulators of MGLUR2-Receptors | GRM2, GRM1, GRM3 | LPL 3999/4885LIPG 4593/4885LMNA 3852/4885 |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | LPL 4234/4885LIPG 4208/4885LMNA 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.